Skip to content
207.878.2770mail@immucell.com
Immucell
Immediate Immunity™
Immucell
  • About ImmuCell
    • About ImmuCell
    • Our Purpose
    • Management and Directors
    • Career Opportunities
    • Contact Us
  • First Defense
    • Product Line Overview
    • Manufacturing Facility Expansion
    • Manufacturing Facility Virtual Tour
    • Testimonials
  • Re-Tain
    • Re-Tain® for Mastitis
    • CMT for Mastitis
  • Sales & Distributors
    • Sales Team
    • Distributors
  • News
  • Investors
  • About ImmuCell
    • About ImmuCell
    • Our Purpose
    • Management and Directors
    • Career Opportunities
    • Contact Us
  • First Defense
    • Product Line Overview
    • Manufacturing Facility Expansion
    • Manufacturing Facility Virtual Tour
    • Testimonials
  • Re-Tain
    • Re-Tain® for Mastitis
    • CMT for Mastitis
  • Sales & Distributors
    • Sales Team
    • Distributors
  • News
  • Investors

STOCK QUOTE

PRESS RELEASES

Recent News | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014
SEC FILINGS
SEC FIlings

XBRL Documents

Annual Report and Proxy
CORPORATE GOVERNANCE
ICCC Code of Conduct

Charter and Powers of the Audit Committee

Nominating Committee Charter

Management & Directors

2017 Press Releases

12-21-2017 ImmuCell Corporation Announces Closing of $3 Million Public Offering of Common Stock

12-19-2017 ImmuCell Corporation Announces Pricing of $3 Million Public Offering of Common Shares

11-13-2017 ImmuCell Announces Financial Results for Third Quarter of 2017

11-13-2017 ImmuCell Achieves USDA Approval of New Product Claim to Prevent Rotavirus Infections

11-07-2017 ImmuCell Announces Completion of Construction of Nisin Production Facility

11-02-2017 ImmuCell to Announce Financial Results for Third Quarter of 2017

09-13-17 ImmuCell Announces Expansion of Sales and Marketing Team

08-14-2017 ImmuCell Announces Financial Results for Second Quarter of 2017

08-07-2017 ImmuCell to Announce Financial Results for Second Quarter of 2017

07-27-2017 ImmuCell Closes $1,000,000 Equity Investment

07-17-2017 ImmuCell Unveils New Website

07-13-2017 ImmuCell Clarifies Number of Authorized Common Shares

05-11-2017 ImmuCell Announces Financial Results for First Quarter of 2017

05-04-2017 ImmuCell to Announce Financial Results for First Quarter of 2017

03-08-2017 Bobbi Jo Brockmann is appointed to Board of Directors of ImmuCell Corporation

03-02-2017 ImmuCell Secures $2 Million in Debt Financing

02-09-2017 ImmuCell Announces Preliminary 2016 Financial Results

02-06-2017 ImmuCell to Announce Preliminary 2016 Financial Results

COMPANY CONTACT

Michael F. Brigham
President & CEO
mail@immucell.com
207.878.2770

INVESTOR CONTACT
Lytham Partners, LLC
iccc@lythampartners.com
602.889.9700

STOCK QUOTE

PRESS RELEASES

Recent News | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014
SEC FILINGS
SEC FIlings

XBRL Documents

Annual Report and Proxy
CORPORATE GOVERNANCE
ICCC Code of Conduct

Charter and Powers of the Audit Committee

Nominating Committee Charter

Management & Directors
Copyright © 2020 ImmuCell Corporation
  • Home
  • About ImmuCell
  • First Defense
  • Re-Tain
  • Sales Team
  • Distributors
  • News
  • Investors
  • Contact Us
Footer Menu
Go to Top
Skip to content
Open toolbar Accessibility Tools

Accessibility Tools

  • Increase TextIncrease Text
  • Decrease TextDecrease Text
  • GrayscaleGrayscale
  • High ContrastHigh Contrast
  • Negative ContrastNegative Contrast
  • Light BackgroundLight Background
  • Links UnderlineLinks Underline
  • Readable FontReadable Font
  • Reset Reset